New Developments in the Treatment of Schizophrenia: An Expert Roundtable.

Joshua T KantrowitzChristoph U CorrellRakesh JainAndrew J Cutler

Published in: The international journal of neuropsychopharmacology (2023)

Results from early clinical trials of agents with novel MOAs are encouraging, particularly for muscarinic and TAAR1 agonists. These agents offer renewed hope for meaningful improvement in the management of patients with schizophrenia.

Keyphrases

clinical trial
bipolar disorder
clinical practice
replacement therapy